Ind Swift Laboratories gets TGA approval from Australia for seven APIs

27 Sep 2011 Evaluate

Ind Swift Laboratories (ISLL), a global pharmaceutical company, has got Therapeutic Goods Administration (TGA) approval from Australia for seven of its APIs - Donepezil HCI, Clarithromycin, Letrozole, Pioglitazone HCI, Ropinirole, Acamprosate and Aripiprazole to be manufactured at its facility at Derabassi. Australia is the most attractive market for pharmaceutical investment in the Asia Pacific region which is primarily due to its growing and ageing population, excellent access to medicines, and fast-recovering economy.

Australia's generics market will be worth $830 million this year, (Australian pharmaceutical market valued around $9 billion) and is expected to grow an average 7% a year, presenting 'huge opportunities' for manufacturers through tapping into the diabetes, oncology, neurological and cardiovascular disease markets.

The company has so far filed 374 DMFs with various regulatory authorities including 05 DMFs filed in Australia. Ind-Swift Laboratories is a part of the Ind-swift Group and is based at Chandigarh, India. The company is engaged in manufacturing of Active Pharmaceutical Ingredients (API). 

Ind-Swift Lab. Share Price

95.90 2.97 (3.20%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×